Strategic partnerships AnaBios collaborates with Fortune 500 pharmaceutical companies, CROs, and universities, presenting a ready network for co-development, licensing, and pilot studies that can accelerate bring-to-market timelines and open doors for new collaboration models.

Ex vivo advantage Their proprietary human tissue platform enables predictive human responses prior to trials, offering a compelling value proposition to pharma with high failure costs in clinical trials, enabling accelerated asset de-risking and go/no-go decisions.

Targeted disease focus Key focus areas include cardiac safety, pain, PKD kidney disease, and neurodegeneration, suggesting opportunities for expanding services, custom tissue assays, and data packages tailored to these therapeutic indications.

Recent growth Acquisition of Cell Systems and strategic hires in business development indicate a push to expand capabilities and geographic reach, creating cross-sell opportunities for tissue products, media, and ex vivo platforms across more markets.

Commercial expansion Existing go-to-market through direct sales and distributors, plus an internal drug discovery platform, provide multiple entry points for offering additional services such as off-the-shelf tissues, custom samples, and functional assays to broaden revenue streams.